High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Australian and New Zealand Lymphoma Study Group.
J Morton, K Taylor, I Bunce, P Eliadis, A Rentoul, D Moore, C Kelly, S Wright, J Bashford, R Rodwell, K Rooney, S Mulligan, F Firkin, A Dodds, J Parkin, R Lowenthal, R Kimber, T Frost, A Grigg, D Goldstein Show all
British Journal of Haematology | Published : 1996
Thirty-five patients (eight de novo, 27 relapsed disease) with low-grade non-Hodgkin's lymphoma (diffuse small lymphocytic, follicular small cleaved cell, follicular mixed cell, and lymphoplasmacytoid) were treated with 2-chlorodeoxyadenosine (2CdA) at a daily dose of 0.14 mg/kg for 5d (2 h infusion) for an average of three cycles. Minor treatment delays, generally due to haematological toxicities, occurred in nine of 105 cycles. Major toxicities were lymphopenia, neutropenia and thrombocytopenia. Opportunistic infections occurred in seven patients. Overall response rate was 69% (five complete, 19 partial) reaching 88% for de novo patients (two complete, five partial). Elevated beta 2-microg..View full abstract